Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 3 | 2024 | 346 | 0.490 |
Why?
|
| Dyslipidemias | 2 | 2024 | 31 | 0.450 |
Why?
|
| Hypertension | 2 | 2025 | 304 | 0.370 |
Why?
|
| Endometrial Neoplasms | 4 | 2013 | 180 | 0.340 |
Why?
|
| Risk Factors | 6 | 2025 | 2009 | 0.230 |
Why?
|
| Gynecology | 1 | 2024 | 55 | 0.220 |
Why?
|
| Obstetrics | 1 | 2024 | 46 | 0.220 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2024 | 44 | 0.220 |
Why?
|
| Coronary Disease | 1 | 2024 | 118 | 0.220 |
Why?
|
| Judgment | 1 | 2023 | 30 | 0.210 |
Why?
|
| Depression | 1 | 2025 | 209 | 0.210 |
Why?
|
| Schools, Medical | 1 | 2023 | 45 | 0.210 |
Why?
|
| Humeral Fractures | 1 | 2022 | 8 | 0.200 |
Why?
|
| Elbow Joint | 1 | 2022 | 22 | 0.200 |
Why?
|
| Aged | 7 | 2025 | 5157 | 0.190 |
Why?
|
| Atherosclerosis | 1 | 2022 | 91 | 0.190 |
Why?
|
| Internship and Residency | 1 | 2024 | 224 | 0.180 |
Why?
|
| Indians, North American | 2 | 2025 | 511 | 0.180 |
Why?
|
| Metformin | 2 | 2012 | 32 | 0.180 |
Why?
|
| Telomerase | 4 | 2013 | 37 | 0.180 |
Why?
|
| Cohort Studies | 4 | 2023 | 857 | 0.170 |
Why?
|
| Adult | 7 | 2025 | 7359 | 0.160 |
Why?
|
| Humans | 16 | 2025 | 26777 | 0.160 |
Why?
|
| United States | 4 | 2025 | 2030 | 0.150 |
Why?
|
| Female | 10 | 2025 | 14421 | 0.140 |
Why?
|
| Young Adult | 4 | 2024 | 2576 | 0.130 |
Why?
|
| Adolescent | 4 | 2024 | 2952 | 0.130 |
Why?
|
| Middle Aged | 5 | 2025 | 6796 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2012 | 68 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 83 | 0.100 |
Why?
|
| Estrogens | 1 | 2013 | 56 | 0.100 |
Why?
|
| Neoplasms | 1 | 2021 | 748 | 0.100 |
Why?
|
| Incidence | 2 | 2025 | 546 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2013 | 1337 | 0.100 |
Why?
|
| Pandemics | 2 | 2024 | 165 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 40 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 129 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2012 | 179 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 93 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 146 | 0.090 |
Why?
|
| Cell Line, Tumor | 5 | 2013 | 1258 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 316 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2024 | 1216 | 0.080 |
Why?
|
| RNA, Messenger | 4 | 2013 | 645 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 364 | 0.080 |
Why?
|
| Male | 4 | 2025 | 12842 | 0.070 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2007 | 1 | 0.070 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2007 | 5 | 0.070 |
Why?
|
| Interleukin-8 | 1 | 2007 | 44 | 0.070 |
Why?
|
| Endocytosis | 1 | 2007 | 81 | 0.070 |
Why?
|
| Cell Cycle | 3 | 2012 | 155 | 0.070 |
Why?
|
| Masks | 1 | 2024 | 9 | 0.060 |
Why?
|
| Phosphatidylcholines | 1 | 2024 | 41 | 0.060 |
Why?
|
| Lipoproteins, LDL | 1 | 2024 | 36 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2024 | 93 | 0.060 |
Why?
|
| Triglycerides | 1 | 2024 | 117 | 0.060 |
Why?
|
| Mortality, Premature | 1 | 2023 | 3 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 400 | 0.050 |
Why?
|
| School Admission Criteria | 1 | 2023 | 6 | 0.050 |
Why?
|
| Apoptosis | 3 | 2012 | 738 | 0.050 |
Why?
|
| Genotype | 1 | 2024 | 441 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2024 | 229 | 0.050 |
Why?
|
| Cholesterol | 1 | 2024 | 182 | 0.050 |
Why?
|
| Hospitalization | 1 | 2024 | 188 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 385 | 0.050 |
Why?
|
| Elbow | 1 | 2022 | 15 | 0.050 |
Why?
|
| Humerus | 1 | 2022 | 10 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 213 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 542 | 0.050 |
Why?
|
| Cell Growth Processes | 2 | 2012 | 18 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 662 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 909 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 915 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1127 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2022 | 1087 | 0.040 |
Why?
|
| Oklahoma | 1 | 2021 | 970 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2022 | 1924 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2022 | 2261 | 0.030 |
Why?
|
| Child | 1 | 2022 | 2141 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2022 | 2426 | 0.030 |
Why?
|
| Butadienes | 1 | 2013 | 14 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 23 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 22 | 0.030 |
Why?
|
| Nitriles | 1 | 2013 | 32 | 0.030 |
Why?
|
| RNA Interference | 1 | 2013 | 135 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 262 | 0.030 |
Why?
|
| Estradiol | 1 | 2013 | 174 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2012 | 100 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 333 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 282 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 130 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 558 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 441 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 323 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2009 | 143 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2011 | 762 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 587 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2007 | 45 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2007 | 52 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2007 | 130 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2007 | 68 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 312 | 0.020 |
Why?
|
| Kinetics | 1 | 2007 | 538 | 0.020 |
Why?
|
| Rats | 1 | 2007 | 1539 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 9932 | 0.010 |
Why?
|